Effect of Oral Aluminium Hydroxide on Iron Absorption from Iron(III)-hydroxide Polymaltose Complex in Patients with Iron Deficiency Anemia a single-centre randomized controlled isotope study

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 6, 2007, Pages 392-400

  Potgieter, Maria A ^a   Potgieter, Johannes H ^a   Venter, Cornea ^a   Venter, Jan L ^b   Geisser, Peter ^c  

^a PAREXEL INTERNATIONAL   (United States)

^b Altana Madaus (Pty) Ltd   (South Africa)

^c Vifor (International) Inc   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; IRON 59; IRON POLYMALTOSE; MALTOFER; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMOGRAPHY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COATING; DRUG EFFICACY; ERYTHROCYTE; FEMALE; HUMAN; IRON DEFICIENCY ANEMIA; IRON TRANSPORT; MALE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; ALGORITHMS; ALUMINUM HYDROXIDE; ANEMIA, IRON-DEFICIENCY; ANIMALS; ANTACIDS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHYSICAL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; ERYTHROCYTES; FEMALE; FERRIC COMPOUNDS; FERRITINS; HUMANS; INTESTINAL ABSORPTION; IRON; IRON RADIOISOTOPES; MALE; MICE; MIDDLE AGED; QUALITY CONTROL; RATS;

EID: 34447332529     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296688     Document Type: Article

References (48)

1. Green FW, Norton RA, Kaplan MM. Pharmacology and Clinical Use of Antacids. Am J Hosp Pharm. 1975; 32: 425.
2. Tuomainen T, Nyyssönen K, Porkkala-Sarataho E, Salonen R, Baumgartner JA, Geisser P et al. Oral Supplementation with Ferrous Sulphate but not With Non-ionic Iron Polymaltose Complex Increases the Susceptibility of Plasma Lipoproteins to Oxidation. Nutr Res. 1999; 19: 1121.
3. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. ArzneimittelForschung (DrugResearch). 1992; 42: 1439.
4. Iron polymaltose complex: toxicity to dogs by repeated oral administration for 52 weeks [report]. Huntingdon: Huntingdon Life Sciences; June 4, 1998.
5. Jacobs P, Wormald LA, Gregory MC. Absorption of iron polymaltose and ferrous sulphate in rats and humans. S Afr Med J. 1979; 55: 1065.
6. Maltoferürg (Iron(III)-hydroxide polymaltose complex) for oral use [periodic safety update report, data on file]. St. Gallen: Vifor (International) Inc.; 2005.
7. Jacobs P, Johnson G, Wood L. Oral iron therapy in human subjects-comparative absorption between ferrous salts and iron polymaltose. J Med. 1984; 15: 367.
8. Kreuzer M, Kirchgessner M. Kinetics of Fe(III)-hydroxide-polymaltose supplied orally, intravenously and intramuscularly to rats as obtained by radiotracer techniques. Trace Elements Med. 1991; 8: 43.
9. Langstaff RJ, Geisser P, Heil WG, Bowdler JM. Treatment of iron-deficiency anaemia: a lower incidence of adverse effects with Ferrum Hausmann than ferrous sulphate. Brit J Clin Res. 1993; 4: 191.
10. Kaltwasser JP, Werner E, Niechzial M. Bioavailability and therapeutic efficacy of bivalent and triavlent iron preparations. Arzneimittel-Forschung (Drug Research). 1987; 37: 122.
11. Jacobs P, Fransman D, Coghlan P Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron-deficient blood-donors. J Clin Apheresis. 1993; 8: 89.
12. Sas G, Nemesanszky E, Bräuer H, Ssheffer K. On the therapeutic effects of trivalent and divalent iron in iron deficiency anaemia. Arzneimittel-Forschung (Drug Research). 1984; 34: 1575.
13. Jacobs P, Wood L, Bird AR. Better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology. 2000; 5: 77.
14. Schmidt BJ, Morais MB, Fisberg M, Martins A, Machado NL. Comparalo terapèutica entre o sulfato ferroso e o ferro trivalente em forma de complexo dehidróxido férrico polimaltosado na deficiència organica de ferro. Fol Med. 1985; 90: 225.
15. Grandjean EM. Scientific report on the clinical safety of the iron(III)-hydroxide polymaltose complex (Maltoferürg). Report SR-1023/E01. August 25, 1997.
16. Mackintosh W, Jacobs P. Response in serum ferritin and haemoglobin to iron therapy in blood donors. Am J Hema-tol. 1988; 27: 17.
17. Murahovschi J, Stein ML, Careffa RC, De Andrade VL, Da Campos Guerra CC, Falci M. Tratamento da ferropenia e da anemia ferropenica com o complexo de hidroxido de ferro polimaltosado por via oral, de crianças em fase de recupe-raçao de infecçoes respiratorias. Ensaio duplo-cego, comparative com sulfato ferroso. Rev Paul Ped. 1987; 5: 97-104.
18. DʼnAmico E, Mazzoni P, Castangna PC. Impiego di un preparato di ferro polimaltosato per via orale nellʼnanemia ferropriva del bambino. Med Praxis. 1986; 7: 1-12.
19. Picchini F, Di Pietro M, Di Battista S, Moretti P, Celommi ML, Natali L et al. Contributo clinico sullʼnuso di un preparato orale a base di ferro polimaltosato (Intrafer). Minerv Ped. 1987; 39: 729.
20. Beruti EJ. Oral treatment of multi-deficiency anaemias of pregnant women with a combination of ferric polymalto-sate, folic acid and vitamin B12 [internal report]. St. Gallen: Vifor International; 1978.
21. Geisser P. In vitro studies on interactions of iron salts and complexes with food-stuffs and medicaments. Arzneimittel-Forschung (Drug Research). 1990; 40: 754.
22. Schaub E, Chovan K, Bürgin M, Renker H, Müller A. Gastrointestinal tolerance of iron haematinics on rabbits. St. Gallen: Hausmann Laboratories; Sep. 20, 1984.
23. Stekel A, Amar M, Calvo E, Chadud P, Hertrampf E, Llaguno S et al. Nutritional significance of interaction between iron and food components. Arch Latinoam Nutr. 1983; 33: 3-41.
24. Bothwell TH, Charlton RW, Cook JD, Finch CA. Iron Metabolism in Man. Oxford-London: Blackwell Scientific Publications; 1979.
25. Sharpe LM, Peacock WC, Cooke R, Harris RS. The effect of phytate and other food factors on iron absorption. J Nutr. 1950; 41: 433.
26. Werner E, Kaltwasser JP, Ihm P Orale Eisentherapie: Intestinale Absorption und ihre Beeinflussung durch eine Mahlzeit. Dtsch Med Wochenschr. 1977; 102: 1061.
27. Heinrich HC. Nüchterneinnahme: Voraussetzung für optimale Bioverfügbarkeit oral verabfolgten Eisens. Dtsch. Med. Wochenschr. 1977; 102: 1699.
28. Zillenssen E. Nüchterneinnahme von Eisenpräparaten: Eine überzogene Forderung. Dtsch Med Wochenschr. 1977; 102: 1893.
29. Layrisse M. Iron intake and iron absorption [Proc. Int. Con-gr. Nutr. 1978]. Nutr Food Sci. 1980; 3: 123.
30. Gillooly M, Bothwell TH, Charlton RW, Torrance JD, Bez-woda WR, Macphail AP et al. Factors affecting the absorption of iron from cereals. Br J Nutr. 1984; 51: 37.
31. Subba Rao K, Narasigna Rao BS. Studies of iron chelation by phytate and influence of other mineral ions on it. Nutr Rep Int. 1983; 28: 771.
32. Graf E, Eaton JW. Effects of phytate on mineral bioavailability in mice. J Nutr. 1984; 114: 1192.
33. Platt SR, Clydesdale FM. Binding of iron by cellulose, lignin, sodium phytate and beta-glucan, alone and in combination under simulated gastrointestinal pH conditions. J Food Sci. 1984; 49: 531.
34. Urushizaki I et al, eds. Structure and function of iron storage and transport proteins. Amsterdam: Elsevier Science; 1983.
35. Disler PB, Lynch SR, Charlton RW, Torrance JD, Bothwell TH. The effect of tea on iron absorption. Gut 1975; 16: 193.
36. Miller J. Effects of glucose, sodium phosphate and ascorbic acid in heat processed diet mixtures on bioavailability of iron. Nutr Rep Int. 1983; 28: 843.
37. Monsen ER, Cook JD. Food iron absorption in human subjects, IV, The effect of calcium and phosphate salts on the absorption of non-heme iron. Am J Clin Nutr. 1976; 29: 1142.
38. Cook JD, Noble NL, Morck TA. Effect of fiber on nonheme iron absorption. Gastroenterology. 1983; 85: 1354.
39. Klaasen CD. Heavy metals and heavy-metal antagonists. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman and Gilmanʼns, The Pharmacological Basis of Therapeutics. 8th ed. New York: McGraw-Hill; 1996.
40. Neuvonen PJ, Gothoni G, Hackman R, Björksten K. Interference of iron with the absorption of tetracyclines in man. Brit Med J. 1970; 4: 532.
41. Heinrich HC, Oppitz KH, Gabbe EE. Inhibition of iron absorption in man by tetracycline. Klin Wochenschr. 1974; 52: 493.
42. Schramm G. Some experiments on the incompatibility of semisynthetic tetracyclines. Schweiz Apoth Ztg. 1976; 114: 361.
43. Geisser P, Müller A. Iron pharmacokinetics after administration of ferric-hydroxide-polymaltose complex in rats. Arzneimittel-Forschung (Drug Research). 1984; 34: 1560.
44. Takano J, Jamano MT, Matsumoto T. Study on the sustained released effect of Ferrum SR Hausmann Capsules. N Drugs Ther. 1976; 25: 2137.
45. Kobler E, Nüesch HJ, Bühler H, Dehyle J, Dehyle P Medikamentös bedingte Oesophagusulcera. Schweiz Med Wochenschr. 1979; 109: 1180.
46. Abbarah TR, Fredell JE, Ellenz GB. Ulceration by oral ferrous sulfate. JAMA 1976; 236: 2320.
47. Hillman RS. Haematopoietic agents: Growth factors, Minerals and Vitamins. In: Hardman JG, Limbird LE, Molinoff PB et al, eds. Goodman and Gilmanʼns, The Pharmacological Basis of Therapeutics. 8th ed. New York: McGraw-Hill; 1996.
48. Hoen B. Iron and Infection: Clinical experience. Am J Kidney Dis. 1999; 34(Suppl 2, 0ctober): S30.